Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial-Reference-Cited by-同舟云学术

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Published:2018-08 Issue:8 Volume:19 Page:1117-1125
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Oza Amit M,Matulonis Ursula A,Malander Susanne,Hudgens Stacie,Sehouli Jalid,del Campo Josep M,Berton-Rigaud Dominique,Banerjee Susana,Scambia Giovanni,Berek Jonathan S,Lund Bente,Tinker Anna V,Hilpert Felix,Vázquez Isabel Palacio,D'Hondt Véronique,Benigno Benedict,Provencher Diane,Buscema Joseph,Agarwal Shefali,Mirza Mansoor R

Publisher

Elsevier BV

Subject

Oncology

Reference17 articles.

1. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann Oncol,2013

2. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy;Hanker;Ann Oncol,2012

3. Platinum neurotoxicity pharmacogenetics;McWhinney;Mol Cancer Ther,2009

4. Psychological well being and quality of life in ovarian cancer survivors;Ferrell;Cancer,2003

5. Transforming the death sentence: elements of hope in women with advanced ovarian cancer;Reb;Oncol Nurs Forum,2007

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer;Journal of Translational Medicine;2024-08-21

2. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial;Gynecologic Oncology;2024-08

3. Gynaecological cancer surveillance for women with Lynch syndrome: systematic review and cost-effectiveness evaluation;Health Technology Assessment;2024-08

4. Real-world TRAE association between niraparib and platinum-based chemotherapy;Frontiers in Oncology;2024-06-17